Publication
Intraocular Pressure in Eyes Receiving Intravitreal Antivascular Endothelial Growth Factor Injections
| dc.contributor.author | Lemos, V | |
| dc.contributor.author | Cabugueira, A | |
| dc.contributor.author | Noronha, M | |
| dc.contributor.author | Abegão Pinto, L | |
| dc.contributor.author | Reina, M | |
| dc.contributor.author | Branco, J | |
| dc.contributor.author | Gomes, T | |
| dc.date.accessioned | 2015-03-24T10:52:35Z | |
| dc.date.available | 2015-03-24T10:52:35Z | |
| dc.date.issued | 2015 | |
| dc.description.abstract | PURPOSE: The aim of the this study was to determine the effect of intravitreal antivascular endothelial growth factor injections on intraocular pressure (IOP) and identify possible risk factors for the development of increased IOP. MATERIALS AND METHODS: This prospective study included a total of 106 eyes receiving intravitreal injection of bevacizumab as treatment for macular edema or active choroidal neovascularization. IOP was measured by Goldmann applanation tonometry immediately before the intravitreal injection and 5 min, 1 h and 15 days after the procedure. The records of the study patients were reviewed for age, gender, history of glaucoma, diabetes mellitus, phakic status, systemic and topical medication and number of previous injections. Subconjunctival reflux was registered. IOP elevation was defined as IOP ≥21 mm Hg and/or a change from baseline of ≥5 mm Hg recorded at least on two or more measurements on the same visit. RESULTS: Mean preoperative IOP was 15.31 ± 3.90 mm Hg and postoperative IOP values were 27.27 ± 11.87 mm Hg (after 5 min), 17.59 ± 6.24 mm Hg (after 1 h) and 16.86 ± 3.62 mm Hg (after 15 days). The IOP variation was statistically significant between pre- and postoperative measurements (p < 0.05). Subconjunctival reflux was recorded in 11.3%, and in this subgroup the IOP at 5 min and at 1 h was lower than preoperative IOP (p < 0.05). CONCLUSIONS: More than one third of the eyes achieved IOPs >30 mm Hg 5 min after injection. Subconjunctival reflux contributed to a lower mean postoperative IOP (p < 0.05). Considerations for the management include prophylactic IOP lowering with medical therapy and/or preinjection ocular decompression for patients with a history of glaucoma or ocular hypertension and switching to an as-needed injection protocol in patients suffering a marked IOP rise in previous injections. © 2015 S. Karger AG, Basel. | por |
| dc.identifier.citation | Ophthalmologica. 2015 Mar 13. [Epub ahead of print] | por |
| dc.identifier.uri | http://hdl.handle.net/10400.17/2062 | |
| dc.language.iso | eng | por |
| dc.peerreviewed | yes | por |
| dc.publisher | Karger | por |
| dc.subject | CHLC OFT | por |
| dc.subject | Angiogenesis Inhibitors/therapeutic use | por |
| dc.subject | Bevacizumab/therapeutic use | por |
| dc.subject | Choroidal Neovascularization/drug therapy | por |
| dc.subject | Intraocular Pressure/drug effects | por |
| dc.subject | Intravitreal Injections | |
| dc.subject | Macular Edema/drug therapy | |
| dc.subject | Prospective Studies | |
| dc.subject | Risk Factors | |
| dc.subject | Tonometry, Ocular | |
| dc.subject | Vascular Endothelial Growth Factor A/antagonists & inhibitors | |
| dc.subject | Aged, 80 and over | |
| dc.subject | Adult | |
| dc.subject | Aged | |
| dc.title | Intraocular Pressure in Eyes Receiving Intravitreal Antivascular Endothelial Growth Factor Injections | por |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.title | Ophthalmologica | por |
| rcaap.rights | openAccess | por |
| rcaap.type | article | por |